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ABSTRACT
Background: Longitudinal cohort studies of Ebola virus disease (EVD) survivors from the 20142016 West African outbreak have found evidence of Ebola virus (EBOV) and EBOV RNA
persistence in the bodily fluids of survivors, particularly in semen. This new evidence has raised the
possibility of sexual transmission of EBOV by EVD survivors. The current interim guidance issued
by the World Health Organization (WHO) recommends safer sex practices for at least 12 months
after acute disease onset (ADO). However, based on new evidence, these recommendations may
require revision.
Objective: The main aim of this article is to present and evaluate evidence on the persistence of
EBOV in genital fluids, as determined by RT-PCR or viral isolation. In addition to determining the
length of persistence in these genital fluids, the relation of persistence to sexual transmission of EBOV
is also examined.
Design: We conducted a systematic review of viral persistence in semen, vaginal, and rectal fluids,
and assessed evidence of the potential transmissibility of persistent EBOV via sexual transmission
from survivors.
Results: We identified 42 published original studies presenting results on EBOV persistence or
reporting on suspected sexual transmission of EBOV from survivors. EBOV RNA has been detected
in the seminal fluids of an EVD survivor for up to 40 months post-EVD onset. From a cohort of
nearly 2,000 male survivors, we estimate an average length of EBOV RNA duration of 370 days.
EBOV has also been detected by viral isolation for up to 82 days. Finally, we report that age is a
potential determinant of EBOV persistence, with older age associated with a higher likelihood of
EBOV RNA detection in seminal fluid.
Conclusion: On the basis of the evidence reviewed, we conclude that persistence of EBOV RNA is
related to an increased risk of sexual transmission of EBOV, though the evidence remains mixed on
whether detectable EBOV RNA necessarily signifies the presence of infectious virus. Due to reports
of intermittent detection of EBOV RNA, especially among survivors who experience EBOV
persistence for over a year, we recommend that at least two negative RT-PCR results be received
before declaring the survivor’s seminal fluid to be cleared of EBOV RNA.
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INTRODUCTION
Ebola virus (EBOV) and Ebola virus disease (EVD)
Since the Ebola virus (EBOV) was first discovered in 1976, the 2014—2016 Ebola virus
disease (EVD) outbreak in West Africa was the largest and most complex Ebola outbreak ever seen.
This outbreak caused more cases and deaths than all previous outbreaks combined. The ongoing
outbreak in the Democratic Republic of the Congo (DRC, formerly the Republic of Zaire), which has
been responsible so far for a total of 823 cases and 517 deaths as of 12 February 2019,1 is currently
the largest outbreak of Ebola in the country’s history. This current outbreak, in combination with the
West African epidemic, has generated a cohort of survivors of unprecedented size. Due to the high
case fatality (CFR) of EVD and the limited number of survivors generated by far smaller epidemics
prior to 2014, little is known about the long-term health impacts of EBOV infection on survivors.
Furthermore, the recognition that EBOV can persist within various immune-privileged sites of the
body, and on occasion be transmitted after long periods of time following “recovery” from acute
disease onset (ADO), has significant public health implications. Although EBOV transmission via
persistently-infected individuals is most often chronicled by partners engaging in sexual activity, the
potential for EBOV resurgence from such events, after successful EBOV control has been declared
within a country, is of significant concern.

Transmission & Evidence of Persistence of EBOV RNA in Bodily Fluids
Fruit bats of the Pteropodidae family are thought to be natural reservoirs of filoviruses, including
EBOV. However, the evidence for a bat reservoir for EBOV is limited to the identification of viral
RNA in tissues obtained from several bat species.2
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The initial introduction of EBOV into humans, prior to subsequent human-to-human
transmission, is believed to occur from interspecies transmission following exposures to “bushmeat”
through butchering or consumption of infected tissues.3 Subsequent human-to-human EBOV
transmission requires close contact with patient blood, vomitus, feces, and fomites (e.g. surfaces and
materials such as bedding) contaminated with these fluids.3 During acute infection, EBOV RNA is
also present in sweat, saliva, and tears.4
EBOV was first isolated in 1976 from seminal fluids of a victim of a laboratory accident. The
virus could be isolated by viral culture from a semen specimen until day 61 after ADO.5 However,
EBOV failed to be isolated after day 76 post EVD-onset.
There is an increasing amount of evidence indicating that EBOV can persist for more than 9
months after clearance of viremia in a number of bodily sites, leading to shedding of the virus in bodily
fluids. Notably, EBOV has been detected by viral isolation or RT-PCR in specimens from immuneprivileged bodily sites such as the testes, the eye, or the central nervous system, which means that the
presence of antigens can be tolerated in these sites without triggering an immune response. This new
evidence provokes the possibility of transmission during the long convalescent period.6-9 Since 2015,
ongoing survivor cohort studies in the three most affected countries of the West African outbreak
(Guinea, Sierra Leone, and Liberia) have been investigating the persistence of EBOV RNA and EBOV
by isolation in semen and other bodily fluids in asymptomatic EVD survivors.
Studies have demonstrated that EBOV can be isolated from semen up to 82 days after
symptom onset,8 and recent viral persistence studies have used nucleic acid amplification tests such as
reverse transcriptase polymerase chain reaction (RT-PCR), to detect genetic material (RNA) from
EBOV up to 965 days (32 months) after ADO.10 These outliers are well beyond the period that
EBOV can be detected in the blood of EVD survivors and long after recovery from illness. The
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persistence of viral genetic material months after symptom onset may reflect the presence of live and
potentially transmissible EBOV.
Although EBOV RNA has been detected by RT-PCR in vaginal fluid from one woman 33
days after symptom onset,8 live virus has never been isolated from vaginal fluid samples. Research on
viral persistence that was conducted after the 2014-2016 EVD outbreak has been unable to
demonstrate the persistence of EBOV in vaginal fluids. With such limited data, it remains unknown
for how long EBOV can typically persist in vaginal fluids.

Evidence of EBOV Sexual Transmission
During the 1967 outbreak of the Marburg filovirus, a close relative of EBOV, a single instance
of heterosexual transmission was documented from a male survivor to female partner, suggesting that
sexual transmission of EBOV could also be possible.11 Since the 2014-2016 outbreak of EVD in West
Africa, male-to-female transmission of EBOV following exposure to the infected semen of the
survivor has been reported or suspected in over 15 instances.12,13 In one such instance from March
2015, EBOV RNA was detected in the semen of a male EVD survivor 199 days after ADO when his
partner fell ill with acute EVD without a reported exposure to another acute EVD case. Matching of
genetic sequences strongly suggested that the route of transmission was sexual.14,15 Female to male
transmission of EBOV is theoretically possible, but seems to be less probable, given the limited
evidence of persistence of EBOV in vaginal fluids.
Den Boon et al. defined viral persistence-derived transmission of EBOV as person-to-person
transmission from an EVD survivor to another person that occurred more than 21 days.16 The 21-day
period was chosen to reflect the upper limit of EVD’s incubation period.3 This definition of viral
persistence-derived transmission of EBOV was used in this review.
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Objectives
For EVD survivors, viral persistence in bodily fluids has potentially significant consequences
for public health guidance. The current interim guidance issued by the World Health Organization
(WHO) recommends safer sex practices for at least 12 months after ADO and apparent recovery.17
The recommended safer sex practices include abstinence from all types of sex or the correct and
consistent usage of a latex condom during any sexual activity. However, these recommendations were
based on studies or reports that had been published up to April 2016, and since then, multiple research
and national semen testing programs have produced additional evidence that must also be considered.
A comprehensive search on both existing literature and unpublished resources can yield important
data on viral persistence in bodily fluids related to sexual transmission that can be used to inform
decisions on public health recommendations for survivors of EVD. The WHO defines an EVD
survivor as a person with a confirmed positive result by RT-PCR testing for EBOV from any bodily
fluid specimen who has subsequently recovered.18 The definition of an EVD survivor can also include
someone who is IgM and/or IgG positive for serological testing of EVD, but has not been vaccinated
against EVD. The term “convalescent” is also used in EBOV literature to describe EVD survivors.
In this review, the terms “convalescent” and “survivor” are used interchangeably.
The primary aim of this article is to present a systematic review on the existing literature
surrounding the persistence of EBOV in bodily fluids related to sexual transmission, particularly
semen, vaginal, and rectal fluids. In addition to determining the length of persistence in these genital
fluids, the relation of persistence to sexual transmission of EBOV is also examined. The ultimate goal
of this systematic review is to provide evidence-based recommendations for revisions of current
WHO guidelines on condom use for EVD survivors.
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METHODS
Searches
Searches were performed in Medline, Embase, Pubmed, Scopus, and CAB Global Health, as
well as in the grey literature sources ClinicalTrials and the WHO International Clinical Trials Registry
Platform. The searches were conducted from 3 to 5 April 2019, with no restrictions on date, language,
or limitations related to study design or geographic location.
The search strategy included medical subject headings (MeSH) and key words for Ebola, in
combination with MeSH and key words for sexual transmission, barrier method contraception, and
body fluids, including semen, rectal, and vaginal secretions. A separate search strategy was developed
to answer three questions relating to EBOV persistence, condom usage, and sexual transmission; these
strategies are presented in Supplementary Table 1. The main search terms were used in different
combinations, using the Boolean operators (“AND” and “OR”) and wildcard variants. The search
strategies were developed in coordination with information scientists at two universities. The search
terms were adapted to suit the syntax of each database, and searches with these defined key words
were limited to the title, keywords, or abstract of the article.

Inclusion Criteria
Since the aim was to find published and unpublished primary data on EBOV persistence in
body fluids and the relation of persistence to sexual transmission, we excluded commentaries,
editorials, protocols, and news reports. Eligible studies included randomized controlled trials (RCTs),
non-randomized controlled trials, controlled before and after studies, interrupted time series, cohort
studies, and case reports. Laboratory, animal, and modelling studies were analyzed separately when
appropriate.
10

Titles and abstracts were screened for inclusion criteria by a single reviewer. If the abstract
was unavailable, the full text of the article was only assessed if the title included at least one of the
following key words or its variations: survivor, convalescence, fluids, persistence, semen, vaginal, condom,
contraception, or sexual transmission. Following the screening of titles and abstracts, the full texts of
relevant articles were then examined by the same reviewer. Papers that met the aforementioned
inclusion criteria were included in the final review. To ensure that primary data points were not
duplicated, articles that reported on the same patient results were grouped together.
Each included study was validated through the creation of a validation assessment table
(Supplementary Table 2). Cases of EBOV infection that were deemed relevant to this review necessitated
laboratory confirmation of a positive EBOV result via viral culture or RT-PCR assay. The presence
of antibodies and other post-disease markers in body fluids were not considered eligible by themselves,
as they only confirm a prior exposure or recovery from acute EBOV infection. Prior studies have
shown that antibodies are widespread in regional populations, including those with no relevant clinical
history.19-21 Each study was assessed based on whether its assay methods were appropriate and
validated, samples were duplicate-tested or compared to controls, and that samples were collected and
stored for a relatively short period of time prior to testing (less than 2 weeks in order to minimize risks
of specimen degradation, unless stored at -80°C or in dry ice or liquid nitrogen).
Data were extracted from the included studies by the same reviewer. Details extracted from
each article included the following: author, year, study setting, reports of sexual transmission from
survivors of EBOV infection, and length of EBOV persistence in body fluids of interest, as evidenced
by RT-PCR or viral isolation.
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RESULTS
Following de-duplication, 706 unique articles were found in Medline, Embase, Pubmed,
Scopus, and CAB Global Health (Fig. 1), and 17 items were found from grey literature on clinical trials.
Of these 723 references included in the title and abstract screening, 148 references were chosen for
full-text review. Seven of these were articles that were cited by relevant studies but not found during
the database search were thus also included in full text review. These articles typically did not show
up in the initial database search because they did not cite the genital fluids of interest in their titles or
abstracts, as screening of genital fluids of EBOV was not the main objective of these studies. After
excluding articles that did not meet the inclusion criteria (n=106), 42 studies were included in the
study. Data were extracted from these articles, and a validity assessment was performed on each study
(Supplementary Table 2).

Figure 1. PRISMA Flow Diagram of Search
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Part 1: Evidence of EBOV Persistence in Genital Fluids

Data on the persistence of EBOV in the genital fluids of convalescents have been amassed
over four EBOV outbreaks, including a 1976 laboratory accident in the United Kingdom, the 1995
outbreak in Kikwit, Democratic Republic of the Congo (DRC), the Sudan EBOV outbreak in 2000
in Gulu, Uganda, and the 2014-2016 West African outbreak. Published data relevant to this review
does not yet exist from the May 2018 outbreak in Équateur province, DRC, or for the current outbreak
in the North Kivu and Ituri provinces of the DRC. Rectal samples were also considered in this study,
as the anus may also be involved in sexual activity.
A total of 25 studies reported data on EBOV persistence in genital and rectal fluids; these
results are summarized in Table 1. While a number of studies were case reports of a single patient, 11
studies reported on large cohort studies of at least 100 EBOV survivors from Sierra Leone, Guinea,
and Liberia during the 2014-2016 West African outbreak. The most commonly used assay to detect
persistence of EBOV in genital fluids was RT-PCR, and most studies defined a positive test as one
with cycle thresholds (Ct) of less than 40 for both viral targets NP and VP40. A result was considered
indeterminant if only one viral target was detected, with the exception of Fischer et al., who considered
any result to be positive if either gene target was detected.22 A prior study by Fischer et al. validated
the use of RT-PCR as an assay for detecting EBOV RNA in body fluid samples.23

Evidence of EBOV Persistence in Semen
The average duration of time for which EBOV RNA was detectable in semen, which was
measured as the number of days to the last positive semen sample, was 370.3 days (standard deviation
= 345.1, n = 448). The persistence of EBOV RNA in semen was calculated as a weighted average of
studies that had provided either individual data or information on mean time between disease onset
and last positive sample (Supplementary Table 3). Some studies reported the duration of EBOV RNA
13

persistence as days since discharge from an Ebola treatment center instead of days from ADO.24-26 To
standardize for this discrepancy during analysis, 14 days were added to these measures to account for
the period of time between ADO and recovery from EVD. Since no estimate for the average length
of recovery from EVD currently exists, the 14 day-estimate was determined using evidence from
several EVD case studies from the 2014-2016 West African outbreak.27-29
Out of 1,926 total convalescents from 25 studies who provided semen specimens, 315 (16.4%)
had at least one positive semen specimen. The longest duration of detection of EBOV RNA was
roughly 40 months, as reported by the Partnership for Research on Ebola Virus in Liberia (PREVAIL
III) cohort study.30 In the PREVAIL III cohort study, 267 male EVD survivors provided a total of
2,416 semen sample. The time from ADO to collection of the first sample ranged from 233 to 1,173
days (median = 551 days). EBOV RNA was detected in at least one semen sample for 81 men
(30.3%).30
Other large cohort studies similarly detected EBOV RNA in seminal fluids of survivors for
over a year after EVD onset (Fig. 2). A study of EVD survivors enrolled in the National Semen Testing
Program in Liberia detected EBOV RNA in the semen of 57 survivors of the 210 survivors (27.1%)
who provided samples.6 The last positive semen sample in the PREVAIL III study was reported at
470 days post-recovery. Another cohort study of male Liberian survivors detected at least one positive
EBOV RNA semen sample in 13 out of 149 survivors (8.7%), with the longest duration of persistence
at 965 days after ADO.22 Similarly, the Postebogui survivors’ cohort study in Guinea found that only
15 of 188 survivors who provided semen samples (8.0%) had at least one semen sample positive for
EBOV RNA.24 The last positive semen sample from the Postebogui cohort was collected 548 days
after the survivor’s recovery.25,31 The Sierra Leone Ebola Virus Persistence Study (VPS) found that 15
out of 120 survivors (12.5%) tested positive for EBOV RNA in at least one semen sample, with the
longest duration of persistence at 406 days after ADO.32
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Table 1. Summary of EBOV Persistence Studies
Reference

Sample
Type

Assay

No. of
Patients

No. of
Patients with
Positive
Sample (%)

No. of Total
Samples

Mean Time
Between
Disease
Onset and
Last Positive
Sample

Latest Day
After
Disease
Onset:
Positive
Sample

Earliest Day
After
Disease
Onset:
Negative
Sample

Abel et al (2017)24

Semen

RT-PCR

188

15 (8.0)

409

190.4 ±
155.1*

497*

518*

Barnes et al (2017)33
Barnes et al (2017)33

Semen
Semen

1
1

1 (100.0)
1 (100.0)

5
5

110
37

180

Bausch et al (2007)4
Bausch et al (2007)4

Semen
Semen

1
1

1 (100.0)
1 (100.0)

2
2

40
40

45

Christie et al
(2015),14 Mate et al
(2015)15
Christie et al (2015)14

Semen

RT-PCR
Viral
isolation
RT-PCR
Viral
isolation
RT-PCR

1

1 (100.0)

1

199

231

1

0 (0)

1

--

Deen et al (2017)6
Diallo et al (2016)7
Emond et al (1977)5

Semen
Semen
Semen

210
1
1

57 (27.1)
1 (100.0)
1 (100.0)

210
Not reported
5

Etard et al (2017)25

Semen

Viral
isolation
RT-PCR
RT-PCR
Viral
isolation
RT-PCR

188

10 (5.3)

Etard et al (2017)25
Fallah et al (2016)34
Fischer et al (2017)22
Green et al (2016)35
Green et al (2016)35
Green et al (2016)35
Knust et al (2016)32

Vaginal
Semen
Semen
Semen
Rectal
Vaginal
Semen

RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR

191
76
149
1
17
21
120

0 (0)
28 (36.8)
13 (8.7)
1 (100.0)
0 (0)
0 (0)
15 (12.5)

Semen

191
76-304

Not reported

470*
531
61

100*
Not done
76

Range: 29548*

548*

Not done

Not reported
771.9 ± 100.9

1
17
21
Not reported

-488
965
114*
--406

Not reported
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Table 1. Summary of EBOV Persistence Studies
Reference

Sample
Type

Assay

No. of
Patients

Knust et al (2016)32

Semen

120

Knust et al (2016)32
PREVAIL III Study
Group (2019)30
Purpura et al (2017)36
Richards et al
(2000)37
Rodriguez et al
(1999),8 Rowe et al
(1999)38
Rodriguez et al
(1999),8 Rowe et al
(1999)38
Rodriguez et al
(1999)8
Rodriguez et al
(1999)8
Rodriguez et al
(1999)8
Rowe et al (1999)38
Rowe et al (1999)38

Vaginal
Semen

Viral
isolation
RT-PCR
RT-PCR

84
267

1 (1.2)
81 (30.3)

RT-PCR
Viral
isolation
RT-PCR

1
1

1 (100.0)
1 (100.0)

1

5

4 (80.0)

11

Semen

Viral
isolation

5

1 (20.0)

11

82

Vaginal

RT-PCR

6

1 (16.7)

15

33

Vaginal

Viral
isolation
RT-PCR

6

0 (0)

15

--

8

1 (12.5)

19

29

19
19

0 (0)
0 (0)

44
44

---

Sissoko et al (2017)9
Sissoko et al (2017)39
Soka et al (2016)40
Sow et al (2016)41

Semen
Semen
Semen
Semen

RT-PCR
Viral
isolation
RT-PCR
RT-PCR
RT-PCR
RT-PCR

26
1
429
68

19 (73.1)
1 (100.0)
38 (8.9)
8 (11.8)

130

Semen
Semen
Semen

Rectal
Vaginal
Vaginal

No. of
Patients with
Positive
Sample (%)

No. of Total
Samples

4 (3.3)

Mean Time
Between
Disease
Onset and
Last Positive
Sample

Latest Day
After
Disease
Onset:
Positive
Sample

Earliest Day
After
Disease
Onset:
Negative
Sample

157

2411

98

Not reported

85.8 ± 17.2

149.6 ± 91.2
Not reported
118.9 ± 79.9

35
40 months
(~1200 days)
565*
19
101

407
Sep 15, 2015
565*
276

603*

62

33

Oct 7, 2015
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Table 1. Summary of EBOV Persistence Studies
Reference

Sample
Type

Assay

No. of
Patients

No. of
Patients with
Positive
Sample (%)

No. of Total
Samples

Srinivas et al (2016)26
Srinivas et al (2016)26

Semen
Semen

1
1

1 (100.0)
0 (0)

8
1

Subtil et al (2017)31

Semen

RT-PCR
Viral
isolation
RT-PCR

188

15 (8.0)

409

Uyeki et al (2016)42
Uyeki et al (2016)42

Semen
Semen

5
5

5 (100.0)
3 (60.0)

25
18

RT-PCR
Viral
isolation

Mean Time
Between
Disease
Onset and
Last Positive
Sample

Latest Day
After
Disease
Onset:
Positive
Sample

Earliest Day
After
Disease
Onset:
Negative
Sample

165*
-231.5 (min 29
- max 551)
184.6 ± 75.3
59.3 ± 10.1

551
290
70

222

Note: * denotes that this value was measured as days after discharge from an Ebola treatment center (ETC)
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Figure 2. Bubble chart depicting average duration of EBOV persistence, as measured by
days after acute disease onset (ADO). Bubble size is proportional to the sample size of each
study.

Detection of EBOV by RT-PCR vs. Viral Isolation in Semen
Though many studies have reported persistence of EBOV RNA in the body fluids of
survivors, the presence of EBOV RNA does not necessarily imply the presence of infectious virus.
In order to establish an association between detection of EBOV RNA by RT-PCR and the presence
of infectious virus, a few studies have attempted to detect EBOV by both RT-PCR and viral isolation
by culture (Fig. 3).
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Figure 3. Bar chart comparing duration of EBOV persistence between viral isolation and
RT-PCR methods, for studies that attempted both assays on the same samples
Note: * denotes that this value was measured as days after discharge from an ETC; † denotes that
this reference includes both Christie et al (2015) and Mate et al (2015), which describe the same
patient

Only five studies were successful in isolating EBOV by viral culture for samples that were
positive for EBOV RNA by RT-PCR.4,5,8,33,42 From these viral culture assays, the longest duration of
persistence of EBOV in seminal fluids of survivors was found to be 82 days after ADO.8 In
comparing the duration of EBOV persistence detectable between these two assays, three studies found
that EBOV RNA could be detected by RT-PCR longer than EBOV could be detected by viral culture
(101 days by RT-PCR vs. 82 days by viral culture,8 290 days by RT-PCR vs. 70 days by viral culture42,
and 110 days by RT-PCR vs. 37 days by viral culture33). The fourth study found the same duration of
EBOV persistence by both RT-PCR and viral culture,4 and the last study only used viral culture to
detect EBOV.5 An abstract from the VPS cohort stated that of the four semen specimens that yielded
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EBOV isolates by viral culture, the longest duration post-EVD onset that viable EBOV was detected
was 157 days.32 This study result was not reported in any other full-text article. Several other studies
also attempted to detect EBOV by viral culture; however, these studies were unsuccessful.14,15,26,38

Evidence of EBOV Persistence in Vaginal & Rectal Specimens
A total of 321 female survivors of EBOV across 5 studies provided vaginal fluid specimens
via vaginal swabs. Only 2 survivors (0.6%) tested positive for EBOV RNA by RT-PCR,8,32 and the last
positive vaginal fluid sample was collected 35 days after ADO (Fig. 2).32 Viral cultures were attempted
from vaginal fluid specimens from 25 survivors up until day 33 after ADO, none of which were
successful.8,38 Out of 25 patients for which rectal specimens were collected,43 only one female survivor
had specimens that were positive by RT-PCR until day 29 after symptom onset, but negative by day
33.8 Viral isolation was not attempted on this sample.

Persistence in Semen by Age
A longitudinal cohort study of EVD survivors in Monrovia, Liberia followed 149 male
survivors who donated semen samples from 260 to 1016 days after ADO.22 The study observed that
older male survivors were significantly more likely to have detectable EBOV RNA in seminal fluids
(median age 41.8 vs 31.2 years, p = 0.0004). Similarly, the Liberia Men’s Health Screening Program,
which provides semen testing services to EVD survivors, found that survivors over the age of 40
comprised 50% of participants with at least one semen sample testing positive for EBOV RNA,
despite accounting for only 23% of the male survivor population in this cohort.40 In one study of
male survivors in Guinea, whose semen specimens were first tested between one to twelve months
after EVD onset, EBOV persistence in semen was detected in eight out of 68 survivors (11%).41 Of
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these 8, the duration of EBOV persistence in seminal fluids averaged 225 days post disease onset for
men over the age of 40, compared to 67.8 days for men under 40.
However, a relation between the duration of persistence and survivor age has not been
universally identified. In a longitudinal study of 26 participants in Guinea, the duration of EBOV
persistence in men older than 40 and in men younger than 40 differed by only 12 days, with older men
experiencing longer persistence.9
In order to elucidate the relation between persistence of EBOV RNA and survivor age, we
extracted data on the participants’ ages at ADO and the number of days between EVD onset and the
last positive EBOV RNA RT-PCR in seminal samples. Eighteen of the 25 studies reported on these
two variables, supplying a total of 54 data points for analysis (Supplementary Table 4). Linear regression
indicated that age was a statistically significant predictor for the duration of EBOV RNA persistence
in semen (p = 0.0003, n = 54), with a positive correlation between age and the duration of persistence
(Fig. 4, Table 2). Survivor age accounted for 21.0% of the explained variability in duration of
persistence.

Table 2. Linear Regression Output for Age & Duration of Persistence
Duration of persistence = -146.47 + 12.90(Age)
Estimate Standard
T-value
Pr(>|t|)
Error
Intercept
-146.47
124.85
-1.17
0.25
Age
12.90
3.32
3.88
0.000296 ***
Residual standard
error
Adjusted R-squared
F-statistic

256.8 on 52 degrees of freedom
0.2096
15.05 on 1 and 52 DF, p-value: 0.000296
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Figure 4. Linear Regression of Age & Duration of Persistence

Intermittent Detection of EBOV RNA in Semen
Several studies have reported intermittent detection of EBOV RNA in semen, with samples
fluctuating between negative and positive results when survivors provided additional samples for
testing over several weeks or months (Fig. 5a, 5b). The Postebogui cohort study in Guinea found that
of the 15 men who had at least one semen sample positive for EBOV RNA, 8 men (53.3%)
experienced fluctuating negative and positive results over multiple days.24,31 For instance, one man
tested negative on day 397 after recovery, positive on day 453, and negative once again on day 463.
Another cohort study of survivors in Liberia found that 8 out of 13 men (61.5%) with positive results
demonstrated intermittent detection of EBOV RNA in seminal fluids, with a positive PCR result
preceded by at least one negative result.22 Of these eight, one participant initially had two negative
samples before a third sample tested positive for EBOV RNA. Similarly, in the PREVAIL III cohort
study, intermittent detection of viral RNA was observed in 78 of the 252 men who provided a semen
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sample (31.0%); 36 of these participants (14.2%) also had two negative PCR tests followed by a
positive. A case study of an EVD survivor from Liberia also reported two negative PCR tests followed
by a positive result.36
Each study also used different brands of RT-PCR assays. Of the studies that reported
intermittent results, the RealStar Filovirus Screen RT-PCR,24,31 the Cepheid Xpert Ebola RT-PCR,22
and the CDC’s Ebola Virus Real-Time RT-PCR36 assays were used. Of the studies that did not report
intermittent results, the EZ1 Real-Time RT-PCR33 and the RealStar Zaire EBOV RT-PCR9 assays
were used. Christie et al. and Mate et al. did not report on which RT-PCR assay was used.14,15

Figure 5a. Survivors with multiple semen samples demonstrating intermittent detection of
EBOV RNA by RT-PCR. Green boxes represent positive tests, while red boxes represent negative
tests. The numbers in each cell indicate the day post-EVD onset on which the sample was collected
and tested. Survivors were included in this figure if individual-level data on RT-PCR results were
provided by the study authors. Authors who provided this data include Abel et al. (2017), Fischer et
al. (2017), and Purpura et al. (2017).
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Figure 5b. Survivors with multiple semen samples that did not demonstrate intermittent
detection of EBOV RNA by RT-PCR. Survivors were included in this figure if individual-level
data on RT-PCR results showed that negative results were retested. Authors who provided this data
include Barnes et al. (2017), Christie et al. (2015), Mate et al. (2015), and Sissoko et al. (2017).

In order to calculate an overall proportion of EVD survivors whose RT-PCR results yielded
intermittent detection of EBOV RNA in seminal fluid, studies that retested negative RT-PCR samples
but did not find fluctuating persistence were included alongside the studies that reported intermittent
detection. In other words, if a study continued testing semen samples even after one negative sample
was received, the study was included in this analysis. This choice was made because many other studies
on EBOV persistence in semen stopped testing participants’ samples after a single negative RT-PCR
result was received; however, these studies might have missed detection of fluctuating persistence
since these negative samples were not retested. Based on this criterion, 9 studies were eligible for this
analysis (Supplementary Table 5), with a total of 303 participants. Intermittent detection of EBOV RNA
was detected in 95 survivors’ seminal samples (31.4%); 38 (12.5%) experienced two negative PCR tests
followed by a positive.
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The samples from these 9 studies on EBOV persistence in seminal samples were then
compared by the following: (1) day post-EVD onset of the last positive EBOV RT-PCR result in
seminal samples, (2) day post-EVD onset of the first “true” negative EBOV result in seminal samples,
(3) total duration of follow-up time for each individual (as calculated by the date of the first sample
subtracted from the date of the last sample), and (4) duration of follow-up time from the last positive
EBOV result to the last sample. In this analysis, a negative RT-PCR result was considered to be a
“true” negative if this result was followed by a second negative RT-PCR result with an interval of at
least one week between tests. Although less than 13% of individuals experienced two negative RTPCR results followed by a positive, current WHO interim guidelines denote that a person is no longer
at risk of sexual transmission of EBOV after two negative tests of semen by RT-PCR.18 Data on these
individual variables can be found in the supplement (Supplementary Tables 6a, 6b). To compare samples
with and without intermittent detection of EBOV RNA, Welch’s two-sample t-test for difference of
means was performed for each of these 4 variables.
This analysis found that the studies with intermittent detection of EBOV RNA had a
statistically significant higher average day of last positive sample (639.2 ± 230.0 days) compared to
participants whose samples did not exhibit intermittent detection (129.6 ± 71.4 days, p-value =
<0.001). Similarly, the samples with intermittent detection had a statistically significant higher average
day of first “true” negative sample (709.2 ± 261.2 days) compared to samples without intermittent
detection (239.3 ± 68.1 days, p-value = <0.001). Average duration of follow-up time was significantly
higher for samples with intermittent detection (260.8 ± 98.9 days) than for samples where intermittent
detection was not observed (115.9 ± 58.0 days, p-value = <0.001). However, for the duration of
follow-up time from the last positive result to the last sample, there was no significant difference
between samples that did observe intermittent detection (159.8 ± 106.1 days) and those that did not
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observe intermittent detection (109.7 ± 53.8 days, p-value = 0.154). These results are summarized in
Table 3.

Table 3. Welch’s Two Sample T-Test for Difference in Means for Intermittent Detection of
EBOV RNA in Semen

Day of Last
Positive
Sample (postEVD onset)
Day of First
“True”
Negative
Sample (postEVD onset)*
Total
Duration of
Follow-Up
Time (days)
Duration of
Follow-Up
from Last
Positive to
Last Sample
(days)

Mean ± SD
Intermittent No
Detection
Intermittent
(n=12
Detection
survivors)
(n=16
survivors)
639.2 ±
129.6 ± 71.4
230.0

95%
Confidence
Interval

tvalue

Degrees of
freedom

p-value

(360.5,
658.6)

7.41

12.6

6.15E-06

709.2 ±
261.2

239.3 ± 68.1

(301.7,
638.2)

6.08

12.1

5.27E-05

260.8 ± 98.9

115.9 ± 58.0

(77.1,
212.5)

4.52

16.6

0.00032

159.8 ±
106.1

109.7 ± 53.8

(-21.1,
121.3)

1.50

15.2

0.154

* A negative RT-PCR result was considered to be a “true” negative if this result was followed by a
second negative RT-PCR result with an interval of at least one week between tests
Modelling Studies on Duration of EBOV Persistence in Semen
A few modelling studies on the persistence of EBOV in semen have been conducted using
viral persistence data from existing cohort studies. One such study fitted a negative binomial
distribution to viral persistence data from a cohort study of 220 adult male survivors in Sierra Leone,6
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combined with weekly disease incidence data from the WHO patient database for Guinea, Liberia,
and Sierra Leone.44 The fitted distribution was used to estimate the number of men in each country
with EBOV RNA detectable in semen for each week, starting from mid-2014. The model projected
that by January 2016, the total number of EBOV RNA semen-positive individuals would decrease
from 2,255 people (95% CI: 1,945-2,495) in January 2015 to just 73 people (95% CI: 15-331) across
all 3 countries by January 2016.44 Another study applied parametric survival models to data from the
Postebogui cohort study in Guinea to estimate the time elapsed between ADO and when EBOV
RNA was no longer detectable in semen by RT-PCR.31 The median time from symptom onset to a
negative RT-PCR test was 46.4 (95% CI: 11-82.6) days. The probability of a survivor’s semen sample
testing positive by RT-PCR decreased from 31.6% at 3 months to 2.9% and 0.7% at 12 and 18 months
post EVD-onset, respectively.31
Time-series data from a longitudinal study of 26 EVD survivors in Guinea were used to model
the dynamics of EBOV persistence in semen over time.9 The linear mixed-effect model, which used
parameters for a hypothetical baseline Ct value at the time of ADO and a clearance rate of EBOV
from semen, predicted that 50% of male survivors would clear EBOV RNA from seminal fluid by
115 days (95% CI: 72-160) post-disease onset and that 90% of male survivors would clear EBOV
RNA from seminal fluid by 294 days (95% CI: 212-399) post-onset.9

Part 2: Sexual Transmission of EBOV from Convalescents and Subsequent EVD

Although detection of EBOV RNA in genital fluids was first reported by Emond et al.’s case
study in 1977,5 reports of likely sexual transmission of EBOV from survivors were first documented
during the 2014-2016 West African outbreak. While the number of EVD survivors has increased
dramatically since earlier outbreaks, data on actual sexual transmission of EBOV from EVD survivors
remain sparse.
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To date, 19 cases of EBOV transmission from convalescent survivors have been reported in
the published literature (Table 4). Of these, 14 cases involved either probable or confirmed sexual
transmission from a male survivor; for the remaining five case, the route of transmission is unknown.
Confirmation of sexual transmission was determined by a combination of epidemiological
investigation, genomic sequencing of EBOV samples, and lack of evidence of contact with an
individual with EVD-related symptoms. The longest duration of detectable EBOV RNA in reported
cases of sexual transmission was found to be 531 days after ADO.7 At the time of transmission, the
survivor was 463 days post-EVD onset, which is the longest duration of persistence at the time of
transmission for the cases in which transmissions dates are known.7 In all cases of probable or
confirmed sexual transmission, semen was the most probable vehicle for EBOV transmission.
However, EBOV isolation by viral culture in sexual transmission studies was either not attempted or
unsuccessful. For cases in which the transmission date was known or highly probable, onset of EVD
usually occurred within 3 weeks of transmission from the survivor (mean = 19.8 days, n = 4). This
finding is consistent with the incubation period of 2-21 days for EBOV infection through other routes
of transmission (i.e. contact with infected blood).3 All cases of sexual transmission were from a male
survivor to their female partner. There were no reports of suspected sexual transmission from a male
survivor to a male partner or of sexual transmission from a female survivor.

Molecular Evidence of Sexual Transmission
Advances in molecular typing through the past few decades have allowed researchers to use
whole-genome sequencing data alongside traditional epidemiological methods to investigate potential
sources and routes of transmission. In July 2015, the Ebola Outbreak Sequencing Support (EOSS), a
collaboration between the Sierra Leone Ministry of Health, the WHO, and the US Centers for Disease
Control & Prevention (CDC), was established to sequence all new EVD cases in Sierra Leone.
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Researchers identified a possible instance of sexual transmission from a survivor more than 50 days
after the last confirmed case in that particular district.45 The EBOV genome from a blood sample
collected from the new acute case was closely related to the EBOV genome from a male survivor who
had recovered from EVD about a month earlier. Sexual contact was reported between the male
survivor and the incident case. The viral genome obtained from the survivor’s semen during
investigations into this new cluster was identical to the viral genome of the survivor’s initial blood
sample, collected 2 months earlier during acute EVD,45 which suggests that the virus was maintained
in a low replicating state within the survivor, even after recovery from acute EVD.
Other studies have exploited similarities between genomic sequences of different EBOV
samples to provide indirect evidence of sexual transmission of EBOV. Five studies investigated 10
new clusters of EVD that appeared months after the last reported case in the same geographic area.16,4549

While epidemiological investigations into these new clusters failed to identify a source of infection,

whole-genome sequencing was able to link the EBOV genomes from the new clusters to genomes
from either a prior circulating strain16,46,47 or from a known survivor,16,45 both of which suggest
transmission from survivors.
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Table 4. Summary of Reports of Transmission of EBOV from a Convalescent
Most
Suspected
Body Fluid

Date of
Recovery of
Survivor

Duration of
Persistence in
Survivor

Total
Cases

Deaths

Virus
Isolation

Unknown, but
likely from
persistence in a
survivor (from
genomic data)
Sexual, probable

Unknown

Unknown

N/A

2

>1

Unknown

Semen,
probable
Unknown

Jul-18, 2015

>51 days

6

>1

Unknown

Unknown

8

2

Unknown

Semen

Oct-7, 2014

10 months
(Probable cases
with reported
potential
persistent
survivor or
matching
sequence
found,
providing
possible
persistence
lengths)
199 days

1

1

Unsuccessful

0

0

N/A

~7 weeks (but
unspecified)

1

Unknown

Unknown

2 months

1

1

Unknown

Country

Acute Case
Date of
Confirmation

Alpren et
al (2016)46

Sierra
Leone

Jan-3, 2016

Arias et al
(2016)45
Blackley
et al
(2016)47

Sierra
Leone
Liberia

Aug-29, 2015

Christie
et al
(2015),14
Mate et al
(2015)15
Christie
et al
(2015)14
Den
Boon et al
(2019)16

Liberia

Mar-20, 2015

Liberia

*no transmission despite 3-5 occasions of unprotected vaginal intercourse (between
Feb-28,2015 – Mar-15,2015)

West
Africa

Unspecified

Unspecified

Sexual, probable

Semen

Unknown

Unspecified

~1-3 weeks
before
symptom onset

Sexual, confirmed

Semen,
probable

Unspecified

Den
Boon et al
(2019)16

Jun-28, 2015

Transmission
Date
(days post
EVD-onset of
survivor, if
known)
Unknown

Transmission
Route

Reference

Aug, 2015 (1444 days)
Jun-1, 2015

Mar-7, 2015
(151 days)

Unknown, but
likely from
persistence in a
survivor (from
genomic data)

Sexual, confirmed

(unspecified
country)

West
Africa

(unspecified
country)
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Table 4. Summary of Reports of Transmission of EBOV from a Convalescent
Reference

Country

Acute Case
Date of
Confirmation

Den
Boon et al
(2019)16

West
Africa

Unspecified

Transmission
Date
(days post
EVD-onset of
survivor, if
known)
Unknown

West
Africa

Unspecified

Unknown

West
Africa

Unspecified

Unknown

Den
Boon et al
(2019)16
Den
Boon et al
(2019)16

(unspecified
country)

(unspecified
country)

Transmission
Route

Most
Suspected
Body Fluid

Date of
Recovery of
Survivor

Duration of
Persistence in
Survivor

Total
Cases

Deaths

Virus
Isolation

Unknown, but
likely from
persistence in a
survivor (from
genomic data)
Unknown, but
likely from
persistence in a
survivor (from
genomic data)
Sexual, probable

Unknown

Unknown

N/A

1

Unknown

Unknown

Unknown

N/A

~5 months
(but
unspecified)

1

1

Unknown

Semen,
probable

Unknown

~5-6 months
(but
unspecified)

1

1

Unknown

Sexual, confirmed

Semen

531 days

13

8

Unknown

Nov-14,
2014
Aug, 2014

Unknown

2

1

Not
attempted
Unknown

Semen,
probable

Dec, 2014

Unknown

2

0

Not
attempted

Unknown

Jan-16, 2015

164 days

1

Unknown

Unknown

Semen,
probable

Unknown

140 days

1

Unknown

Unknown

(unspecified
country)

Diallo et
al (2016)7
Dokubo
et al
(2018)48

Guinea

Mar-16, 2016

Liberia

Nov-19, 2015

Keita et al
(2016)49

Guinea

Oct-13, 2015

Feb-20, 2016
(463 days)
Oct, 2015
(likely, but
unconfirmed)
(396-456 days)
Unknown

Lee et al
(2017)50
Lee et al
(2017)50

Liberia

Jun-29, 2015

Unknown

Unknown, but
likely via bodily
fluids or close
contact
Unknown, but
likely close
contact with body
fluids* (but sexual
transmission
from survivor to
wife, then from
wife to brother
who was the
index case)
Sexual, probable

Guinea

Mar-17, 2016

Unknown

Sexual, probable
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Table 4. Summary of Reports of Transmission of EBOV from a Convalescent
Reference

Lee et al
(2017)50
WHO51
(2015)
Thorson
et al
(2016)12
Thorson
et al
(2016)12
Thorson
et al
(2016)12

Transmission
Route

Most
Suspected
Body Fluid

Date of
Recovery of
Survivor

Duration of
Persistence in
Survivor

Total
Cases

Deaths

Virus
Isolation

Jan-14, 2016

Transmission
Date
(days post
EVD-onset of
survivor, if
known)
Unknown

Sexual, probable

Unknown

123 days

1

Unknown

Unknown

Sep-12, 2015

Unknown

Sexual, probable

Semen,
probable
Unknown

Unknown

Unknown

1

1

Unknown

Unspecified

Unknown

Sexual, probable

Semen,
probable

Unknown

Unknown

1

Unknown

Unknown

Liberia

Unspecified

Unknown

Sexual, probable

Semen,
probable

Unknown

Unknown

1

Unknown

Unknown

Liberia

~Nov, 2014
(but
unspecified)

Unknown

Sexual, probable

Semen,
probable

Unknown

Unknown

1

Unknown

Unknown

Country

Acute Case
Date of
Confirmation

Sierra
Leone
Sierra
Leone
Liberia
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A prior study by Rodriguez et al. tested the genomic stability of EBOV by sequencing a highly
variable region of the GP gene, which encodes for a viral envelope glycoprotein, in multiple samples.8
These samples were chosen from patients who were known to be within the same chain of direct
human-human transmission. The authors found that samples demonstrated high sequence similarity
for this highly variable region, suggesting that similarities in EBOV genomes between two different
patients may be indicative of direct transmission.8 Based on the Rodriguez et al. study findings, several
studies that had previously identified a convalescent survivor as the source of infection for an incident
EVD case through an epidemiological investigation were able to compare EBOV genome sequences
between the convalescent and incident cases. Sequencing data from these studies found a high level
of similarity in the EBOV genome, suggesting that sexual transmission did indeed occur.7,14-16,39,48,49
In transmission reports in which a specific survivor was identified as the source of infection,
researchers observed reduced rates of EBOV evolution during persistent infection, despite months or
even years of elapsed time between samples. For instance, the EBOV genome from one survivor’s
blood sample during acute infection differed from that in his semen sample by only 5 nucleotide
substitutions, despite being collected 504 days prior to the collection of the semen sample.7 The
resulting evolutionary rate for this convalescent semen sample was roughly 6 times slower than that
of the average evolutionary rate seen in acute human-to-human transmission in the West African
outbreak.7 This finding, along with similar results in other studies,15,45,47,49 suggests that persistent
EBOV exhibits reduced evolutionary rates in survivors.
Barnes et al. reported EBOV RNA detected by RT-PCR from a 34-year-old survivor from
Sierra Leone, whose seminal fluid was RT-PCR positive 110 days after ADO.33 To determine whether
the EBOV in the semen sample was actively replicating within cells or if it persisted only as
extracellular virions, the authors used strand-specific RNA methods to compare levels of genomic
viral RNA versus viral antigenomic RNA (cRNA) and messenger RNA (mRNA). The levels of cRNA
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and mRNA detected in samples from 32 days to 110 days after ADO were similar to the levels found
in acute-EVD blood samples, suggesting active viral replication the survivors’ semen. Barnes et al. not
only reported high concentrations of replication-competent virus in semen, but also decreased viral
diversification during persistence.33

Modelling Studies on EBOV Sexual Transmission by Convalescents
To quantify the importance of EBOV viral persistence-related sexual transmission in
increasing the number of cases and duration of the epidemic, several studies developed models that
accounted for sexual transmission from convalescent survivors. One model used weekly incidence
data from EVD cases in Sierra Leone and found that, for a fixed 0.1% transmission probability per
sexual contact, a 3-month duration of EBOV persistence created very few additional cases but
extended the epidemic by 83 days on average.52 They estimated that a 6-month duration of EBOV
persistence extended the epidemic by 540 days, which was double the length of the 2014-2015 Sierra
Leone Ebola epidemic.52 Another modelling study found that sexual transmission by convalescents
is a significant factor in determining the risk of EVD recurrence in areas that were previously declared
transmission free.53 The authors reported that public health officials may need to wait up to one year
after the last EVD case before declaring the end of the epidemic, though this wait time could decrease
if survivors routinely practice safer sex or sexual abstinence.53 A modelling study on EVD intervention
efficacies fit an SIR compartmental model to predictive EVD transmission patterns and found that
post-recovery condom usage by all recovered patients could reduce the number of EVD cases by 26%
and shift the peak of the epidemic curve earlier by 19 days.54 Another study used daily cumulative
cases from West Africa to fit a compartmental model that considered contact with infectious
individuals, contact with dead bodies, and sexual transmission from convalescent survivors; the
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authors found that sexual contact with convalescent patients had significant effects on increasing the
basic reproduction number R0.55

Animal Studies of Sexual Transmission Potential
A study on the transmission potential of persistently-infected survivors inoculated
immunodeficient mice with semen samples from eight convalescents who had previously tested
positive for EBOV RNA by RT-PCR.9 Infectious virus was detected by culture in 15 out of 26 (58%)
specimens that were tested in the mice, and these mice subsequently developed EVD. Another animal
model study described EBOV persistence in convalescent rhesus monkeys that were experimentally
infected. The authors detected EBOV RNA in eye, testicle, or brain tissues in 11 out of 112 survivors
(9.8%) from samples that were collected 43 days post-exposure.56 In contrast, EBOV RNA was not
detected in liver, lymph node, or spleen tissues, which are common target tissues during acute EBOV
infection. Notably, multiplex fluorescence in situ hybridization discovered not only the EBOV
genome, but also the EBOV antigenome in the eye, epididymis, and brain of survivors, which are
immune-privileged sites. Taken together, this data suggests ongoing EBOV replication at the time of
sample collection.56

Prevention of Sexual Transmission through Condom Use by Male EVD Survivors
The use of condoms by EVD survivors during sexual activity remains inconsistent. Sixty-five
percent of participants in the Postebogui survivor cohort study in Guinea (n=664) reported sexual
activity without a condom since recovery, including 48% of those with a semen sample that tested
positive for EBOV RNA by RT-PCR (n=491).34 Liberia’s Men’s Health Screening Program found
that 427 of 466 participants (92%) reported being counselled by EVD treatment unit (ETU) staff to
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either abstain from sexual activity or to use condoms for 90 days post-recovery, as recommended by
WHO interim guidelines for survivors at the time.40 At the time of enrollment, which ranged from 7
days to 697 days post-EVD recovery (median = 384 days), 424 (91%) participants reported having
resumed sexual activity. Of the 410 participants who reported the date that they resumed sexual
activity, 363 (89%) waited at least 90 days after discharge from an ETU before resuming sexual activity.
Of the 424 participants who reported resuming sexual activity, 190 (45%) reported using a condom
the last time they had intercourse.40

DISCUSSION
This is the first systematic review on the persistence of EBOV in genital fluids and its relation
to sexual transmission since Thorson et al. in 2016.12 Our review captures recent evidence released by
national semen testing programs and cohort studies that followed survivors from the 2014-2016 West
African EVD outbreak. The WHO’s interim guidelines on clinical care for EVD survivors were last
revised in April 2016.18 Currently, the WHO recommends safer sex practices for at least 12 months
for EVD survivors who have not had their semen tested. The evidence reviewed here suggests that
EBOV can persist in the seminal fluids of survivors for longer than 12 months, which justifies the
need for a reassessment of these guidelines.
In this review, we provide quantitative estimates of the length of EBOV persistence in semen,
vaginal, and rectal fluids and report on the transmission potential of persistent EBOV. Among almost
2,000 male EVD survivors, more than 16% had at least one RT-PCR positive semen sample result
during convalescence or post-recovery, indicating that viral persistence in semen is not a rare
occurrence. EBOV RNA was detected in semen by RT-PCR for up to 40 months,30 which far exceeds
the WHO’s 12-month recommendation for safer sex practices among EVD survivors. Across studies
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included in this review, EBOV RNA persisted in semen for an average of 370 days, which also suggests
the need to reassess the interim WHO guidelines. Data on viral persistence in semen is right-censored;
for five studies included in this review, some participants were still RT-PCR positive for EBOV RNA
in semen when the study ended.22,30,35,41,57 This suggests that the average duration of persistence of
viral RNA is likely an underestimate.
Of the more than 300 female survivors whose vaginal fluids were tested for EBOV persistence
up to 35 days post-EVD onset, less than 1% were RT-PCR positive for EBOV RNA. This low
proportion is consistent with previous studies of EBOV persistence in vaginal fluids.8,38 The longest
duration of EBOV RNA persistence was 35 days across the 321 vaginal fluid samples that tested
positive.32 Similarly, while 25 rectal samples were tested, the last rectal sample tested positive for
EBOV RNA at 29 days.8
The detection of EBOV RNA in genital fluids does not necessarily imply that the sample is
infectious; evidence on the transmission potential of persistent EBOV RNA in genital fluids was also
evaluated. From studies that attempted viral cultures of RT-PCR positive genital fluid samples, the
maximum time at which EBOV was isolated was 82 days post-EVD onset from a semen sample.8 No
EBOV has been successfully isolated from vaginal or rectal samples. Only 5 studies have successfully
detected EBOV by viral culture in convalescent seminal fluids.4,5,8,33,42 This could be related to the
small number of studies that attempted viral isolation, to publication bias, or to the inactivation of the
virus by standard practices of storing and freezing specimens.8
The most direct link between persistent EBOV RNA detection in seminal fluids and evidence
of infectiousness was established by Sissoko et al. Seminal fluid specimens from EVD survivors, with
persistent EBOV RNA detected at a median duration of 158 days after ADO, were inoculated into
immunodeficient mice.9 Infectious virus was detected in more than half of the specimens tested in
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the mice. Subsequent EBOV infection of these mice indicates that EBOV RNA detected by RT-PCR
in seminal fluid may be indicative of infectious viral particles.
A study by Barnes et al., which used semen samples from a male EVD survivor with EBOV
RNA detected up to 110 days post-EVD onset, found high concentrations of replication-competent
virus in viral cultures.33 A consistent result across this study and a number of other studies that
examined genomic sequencing data was that EBOV RNA exhibited decreased viral diversity during
persistence, with very few nucleotide substitutions between fluid samples that were collected months,
and even years, apart.15,33,45,47,49 In other words, in persistent EBOV RNA samples, EBOV can be
maintained in a low replicating state, but with an evolutionary rate that is reduced compared to that
seen during acute human-to-human transmission. To explain the reduced evolutionary rate, Blackley
et al. and Diallo et al. suggest that EBOV in immune-privileged sites such as the testes might experience
a reduced rate of viral replication;7,47 persistence of the EBOV RNA could then be explained by the
characteristic reduction of immune clearance seen in immune-privileged sites.58 However, Barnes et
al.’s discovery of high amounts of EBOV cRNA and mRNA in semen from EVD survivors strongly
suggests the presence of replicating virus in seminal fluid cells.33 Instead, because evolutionary rates
are dependent on replication and mutation rates, as well as selective pressures, the reduced EBOV
evolutionary rate could be related to reduced selection within immune-privileged sites such as the
testes rather than reduced replication.
Diallo et al. indicates that one explanation for EBOV persistence that cannot be ruled out is
that the survivor was sub-clinically re-infected with EBOV following recovery. However, this is
unlikely because there has not yet been a documented, laboratory-confirmed case of EBOV
reinfection.7 Similarly, in every study, blood samples that were collected concurrently with semen
samples from EVD survivors tested negative by RT-PCR, which indicates the lack of an acute
infection. The lower-than-expected number of mutations observed in the EBOV genome from
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persistent samples also renders it unlikely that this survivor is a subject of an undetected chain of
human-to-human transmission among acute cases.
Genomic techniques have been implemented alongside traditional epidemiological methods
to investigate clusters of EVD that cannot be temporally, geographically, or epidemiologically linked
to any known existing acute EVD cases. Multiple studies have employed genome sequencing to
characterize uncertain sources of infection, with direct human-to-human transmission suggested by
high sequence similarities between EBOV samples from a survivor and the new, acute case.7,14-16,39,45,48,49
In almost all cases of EBOV transmission that implicated a recovered survivor, sexual transmission
via persistently-infected semen was the most suspected route. Given the link between EBOV RNA
detection and infectious viral particles described in the virologic studies above, combined with EBOV
genomic analyses, sexual transmission from a survivor poses a plausible risk for initiating subsequent
cases of EVD. However, cases resulting from this transmission route appear to be few, as this route
has been suggested in fewer than twenty reports. All of the cases of potential sexual transmission
from a survivor described male-to-female transmission, with no evidence of female-to-male
transmission. This is consistent with the lack of conclusive evidence of EBOV persistence in vaginal
fluids.
However, it is important to note that not every sexual exposure with an EVD survivor
necessarily results in sexual transmission. Christie et al. and Mate et al. described molecular evidence
of sexual transmission from a male, EVD survivor, resulting in a new, acute case of EVD.14,15 The
survivor also reported multiple instances of unprotected vaginal intercourse with another woman,
which took place around the same time as the survivor’s contact with the acute EVD case. The other
woman did not develop EVD, and serologic testing for antibodies was negative, indicating no prior
EBOV infection. This inconsistency suggests that there may be other undescribed factors that place
some people at a higher risk of contracting persistence-derived EVD from a survivor.
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With regards to age and persistence, we found that age was a statistically significant predictor
of EBOV RNA persistence in semen, which confirms the findings from two other cohort studies.
Soka et al. and Fischer et al. first described a significant association between the age of the survivor
and persistence of EBOV RNA in semen, with men over 40 years old more likely to have detectable
EBOV RNA in seminal fluids.22,41 In contrast, Sissoko et al. did not detect a significant association for
age and persistence.9 However, the small sample size of this study (n=26), in contrast to Fischer et al.
(n=149) and Soka et al. (n=429), could explain this discrepancy. Moreover, the participants in Sissoko
et al.’s study skewed towards the younger ages (median=31 years, IQR 26-40 years). These two factors
suggest that the study may have had insufficient statistical power to detect a significant association
between older men and persistence of EBOV RNA in semen. Taken together, these findings hint
that older age is a potential determinant of EBOV persistence, and our analysis also finds that older
age is significantly correlated with a longer length of persistence. While age may be a proxy for other
risk factors, this finding is plausible due to age-related changes in immune functioning, as immune
senescence from natural aging may allow for persistence of EBOV into immune-privileged sites such
as the testes.59
A final concern to consider in revising clinical guidelines for EVD survivors relates to reports
of intermittent detection of EBOV RNA by RT-PCR in multiple cohort studies.23,24,30,36 From our
sample of 300 survivors, for which individual RT-PCR results were provided, we estimate that over
30% of participants received a negative RT-PCR result for a semen sample followed by a positive
result weeks or months later. Over 12% of participants even received two negative RT-PCR results
prior to a positive result. We also found that studies that reported intermittent results observed a later
average day post-EVD onset of the last positive RT-PCR sample and also followed survivors for a
longer period of time, compared to studies that did not report intermittent results. The high rate of
intermittent results in select studies could potentially be explained by increased difficulties in detecting
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EBOV RNA as time passes, since Ct values have been shown to increase over time and approach the
threshold of positivity set at Ct=40.6 Another possible explanation is that because studies with high
rates of intermittent results followed survivors for a longer period of time, they were better able to
capture patterns of intermittent detection, compared to other studies that may have stopped following
survivors after a single negative RT-PCR result was received. This explanation is further supported
by the right-censoring observed in the data from 5 studies, who reported participants who were still
positive by RT-PCR for EBOV RNA by the time the study ended.22,30,35,41,57 For instance, Sissoko et al.
reported 3 individuals who were still positive for EBOV RNA by their last semen sample.9 Further
testing of seminal fluids may have revealed either an intermittent pattern or an even longer duration
of persistence.

Limitations
There are a few limitations to our review. Due to the constraints of having only one reviewer,
selection of studies during the initial screening process may be subject to bias. For similar reasons, a
validity assessment was performed in lieu of the more time-intensive GRADE process, which could
mean that the inclusion of some of the final selected studies may not have been fully validated. Some
of the same individuals were reported in different studies (e.g. Christie et al. and Mate et al., or
Rodriguez et al. and Rowe et al.). Where possible, we corrected for this to avoid instances of the same
individual contributing multiple times to estimates such as average duration. However, there remains
a small chance that a few individuals were double-counted.
Our analyses were limited by our lack of access to individual-level data. Some analyses, such
as those conducted for intermittent detection of EBOV RNA and for the association between age
and persistence, were limited to publications that included subject-level data. A few cohort studies
that were included in this review also did not consistently report variance data for our primary outcome
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of interest, the duration of EBOV persistence. For instance, Subtil et al. reported only a minimum and
maximum for duration of EBOV persistence rather than providing data on the variance.31
Finally, we focused our attention on EBOV persistence in semen, vaginal fluids, and rectal
samples because we were interested in the relation between EBOV persistence and sexual
transmission. Contact with urine, fecal matter, or other bodily fluids not included in this review may
also occur during sexual activity. Few studies estimated EBOV RNA persistence in these bodily fluids,
so it is unlikely that this exclusion would have had a significant impact on our analyses.4,5,8,35,38

Conclusions
EBOV RNA has been detected in the seminal fluids of an EVD survivor for up to 40 months
post-EVD onset. After synthesizing all published evidence from 42 studies, representing nearly 2,000
male survivors, the average duration of EBOV RNA in semen was 370 days post-EVD onset. Given
these results, we suggest that the WHO consider revising their current recommendation that EVD
survivors who have not had their semen tested practice safer sex for at least 12 months. Our review
indicates that persistence of EBOV RNA is related to an increased risk of sexual transmission of
EBOV. Due to reports of intermittent detection of EBOV RNA, especially among survivors who
experience EBOV persistence for over a year, we recommend that at least two negative RT-PCR
results be received before declaring the survivor’s seminal fluid to be cleared of EBOV RNA. Finally,
we report that age is a potential determinant of EBOV persistence, with older age associated with a
higher likelihood of EBOV RNA detection in seminal fluid.
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APPENDIX
Supplementary Table 1. Key search terms used and their combinations. The search strategy
described below was used for Ovid(Medline). The search terms were subsequently adapted to suit
the syntax of each database.
Questions 1 & 2
How long do Ebola virus
and Ebola viral RNA persist
in semen, vaginal, and rectal
fluids, by sex? Is the
persistence of Ebola viral
RNA related to sexual
transmission of EBOV?

Question 3
Does consistent and correct
condom use reduce
transmission of Ebola virus?

Questions 4 & 5
How long after the
resolution of EVD-related
symptoms does a male
partner need to use a latex
condom with his male or
female sexual partners? For
how long, following the
resolution of symptoms,
should a man who recovered
from EVD continue to have
his semen tested?

Search Terms
1. exp Ebola virus/ OR exp Hemorrhagic Fever, Ebola/
2. (Ebola or EBOV or ebolavirus).ti,ab,kw.
3. 1 OR 2
4. exp semen/ OR exp rectum/ OR exp vagina/
5. semen.ti,ab,kw. OR seminal.ti,ab,kw. OR testes.ti,ab,kw.
OR vagina*.ti,ab,kw. OR cervix.ti,ab,kw. OR
cervical.ti,ab,kw. OR faeces.ti,ab,kw. OR feces.ti,ab,kw.
OR fecal.ti,ab,kw. OR rectum.ti,ab,kw. OR rectal.ti,ab,kw.
OR anus.ti,ab,kw. OR anal.ti,ab,kw.
6. 4 OR 5
7. 3 AND 6
1.
2.
3.
4.

exp Ebola virus/ OR exp Hemorrhagic Fever, Ebola/
(Ebola or EBOV or ebolavirus).ti,ab,kw.
1 OR 2
exp condom/ OR exp contraception, barrier/ OR exp
safe sex
5. condom.ti,ab,kw. OR barrier method.ti,ab,kw. OR safe*
sex.ti,ab,kw.
6. 4 OR 5
7. 3 AND 6
1.
2.
3.
4.
5.

exp Ebola virus/ OR exp Hemorrhagic Fever, Ebola/
(Ebola or EBOV or ebolavirus).ti,ab,kw.
1 OR 2
exp sexually transmitted diseases/ OR exp coitus/
coitus.ti,ab,kw. OR sex.ti,ab,kw. OR sexual*.ti,ab,kw. OR
intercourse.ti,ab,kw. OR penetrative.ti,ab,kw. OR
penetration.ti,ab,kw.
6. 4 OR 5
7. 3 AND 6

47

Supplementary Table 2. Validity Assessment of Included Studies
Study

Abbate et
al (2016)

Abel et al
(2017)

Alpren et
al (2016)

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
N/A; the study's
purpose was to
develop a
mathematical model
for studying sexual
transmission from
convalescent
survivors
Unclear, probably
yes.

Unclear, probably
yes, in accordance
with WHO sample
collection and
testing standard
operating protocols

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

The model was fitted to data N/A
from weekly incidence of
confirmed and probable
cases in Sierra Leone (20142015) from the WHO
patient database.

Yes. Aim: "to investigate the potential impact of
convalescent sexual transmission on the
transmission dynamics in general, and on the tail
of the epidemic in particular, to understand how
long that vigilance might remain critical."

Semi-quantitative RT-PCR
assay, with positive results
confirmed by a second RTPCR targeting viral
nucleoprotein sequences.
The Ct* cut-off for positive
results was <40.
Positive result by
postmortem buccal swab
tested by RT-PCR for
deceased patient, or RTPCR of blood samples for
living patients

Yes, duplicatetested

Yes. The aim was to investigate "questions about
the longterm persistence of Ebola virus in semen
and how long surveillance of survivors should be
maintained."

Unclear, but
likely yes for
living patients

Yes. Aim: to detail a new chain of transmission
occurring in Sierra Leon 4 months after the the
last reported case.
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Study

Arias et al
(2016)

Barnes et
al (2017)

Bausch et
al (2007)

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
Unclear, probably
yes.

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

Collected blood samples or
Yes, duplicatebuccal swaps; positive if RT- tested
PCR results had Ct values
<40

Yes. Aim: to use genome sequencing to "identify
unconventional transmission chains involving
body fluids, including semen"

Yes, serum and
blood samples were
collected and tested
daily from day 7 to
day 30 postsymptom onset, then
semen samples from
day 32 to day 244
Yes, samples were
placed into cryovials
and stored at
ambient temperature
for <6 hours before
being stored in
liquid nitrogen

RT-PCR assay, with positive
results for Ct values <40;
also viral isolation by tissue
culture

Unclear

Yes. Aim: to "[utilize] reverse-transcription
quantitative polymerase chain reaction (RTqPCR) and deep sequencing to determine
concentration of viral RNA, replicative capacity,
and viral evolution in blood and semen of a
single EVD patient over 110 days of illness"

ELISA antigen positive or
RT-PCR positive;
considered to be
convalescent if they were
previously a confirmed clase,
but whose ELISA antigen
and RT-PCR results had
reverted to negative

Yes, duplicatetested by both
culture and realtime RT-PCR

Not exactly sexual transmission. Aim: "To better
understand the precise modes of transmission,
we sampled various clinical specimens from
patients as well as from environmental surfaces"
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Study

Blackley
et al
(2016)
Christie et
al (2015)

Deen et al
(2017)

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
Yes, samples were
tested within 1 day

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

RT-PCR positive results

Unclear

Unclear, probably
yes.

Positive result by RT-PCR

Unclear

Yes, specimens were
refrigerated for no
longer than 3 days

RT-PCR assays were
performed that targeted
EBOV NP and VP40 gene
targets. A specimen was
considered positive if the
NP and VP40 gene targets
were both detected within
40 cycles of replication.
RT-PCR positive results

Unclear

Yes. Aim: "use epidemiological and genomic data
to investigate the source of the second Liberian
flare-up, centered in Margibi County"
Yes. Aim: " describes the investigation by the
Government of Liberia and international
response partners of the source of Liberia’s latest
Ebola case and discusses the public health
implications of possible sexual transmission of
Ebola virus"
Yes. Aim: "describes the participants’
characteristics at entry in the cohort of male
survivors of EVD whose semen was tested by
means of RT-PCR"

N/A

Yes. Aim: "describe a series of EBOV
transmission events with evidence of
transmission related to viral persistence in EVD
survivors"

RT-PCR positive results

Unclear

Yes. Aim: "report on an Ebola virus disease
(EVD) survivor who showed Ebola virus in
seminal fluid 531 days after onset of disease"

Den Boon N/A; the study's
et al
purpose was to
(2019)
report on possible
viral persistence
derived transmission
based on
epidemiological data
Diallo et
Unclear, probably
al (2016)
yes.
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Study

Dokubo
et al
(2018)

Eggo et al
(2015)

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
N/A; the study's
purpose was to
investigate
epidemiological links
of a cluster of new
cases
N/A; modeling
study

Emond et
al (1977)

Unclear, probably
yes, as this person
was hospitalized
Etard et al Unclear, probably
(2017)
yes.
Fallah et
al (2016)

Unclear, probably
yes.

Fischer et
al (2016)

N/A; the study's
purpose was to
assess the efficacy of
detecting EBOV in
semen and to
determine the

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

Positive laboratory result for
Ebola virus antigen by
reverse transcriptase
qualitative PCR (RT-PCR)
detection of virus RNA or
by detection of anti-Ebola
IgM antibodies
N/A

N/A

Not exactly sexual transmission. Aim: "Case
investigations were done to ascertain previous
contact with cases of Ebola virus disease or
infection with Ebola virus."

N/A

Positive by viral culture

Unclear

"Laboratory-confirmed
EVD," likely positive by
RT-PCR
RT-PCR positive results

Unclear

N/A

N/A

Yes. Aim: "to estimate the current number of
semen-positive men in affected West African
countries"
Yes. This was a case report that also happened to
describe EBOV isolated from convalescent
semen specimens
Yes. Aim: " to assess long-term clinical,
psychosocial,and viral outcomes in EVD
survivors in Guinea"
Yes. Aim: "To characterize the clinical sequelae
in survivors and to assess whether they can
transmit infection to household members and
sexual contacts"
Yes. Aim: "We assessed the efficiency of
detecting Ebola virus in semen samples by
molecular diagnostics and the stability of Ebola
virus in ex vivo semen under simulated tropical
conditions"

Unclear
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Study

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
stability of EBOV in
ex vivo semen

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

Fisher et
al (2017)

Yes, semen was
tested for EBOV
RNA within 2 days
of collection

Samples were considered
positive if either target gene
(GP or NP) was detected by
RT-PCR

Unclear

Green et
al (2016)

Unclear, probably
yes

RT-PCR assay, with positive
results for Ct values <40

Guo et al
(2016)

N/A; modeling
study

N/A

Samples were
retested if Ct
values were 3740
N/A

Yes. Aim: " describes the investigation by the
Government of Liberia and international
response partners of the source of Liberia’s latest
Ebola case and discusses the public health
implications of possible sexual transmission of
Ebola virus"
Yes. Aim: "to better inform necessary protective
measures for health-care providers, behavioural
modification advice for survivors"

Keita et al
(2016)

Unclear, probably
yes

Positive result by RT-PCR

Unclear

Knust et
al (2016)

Unclear, probably
yes

Positive result by RT-PCR

Unclear

Yes. Aim: "to predict epidemic trends and
evaluate intervention measure efficacy following
the 2014 EVD epidemic in West Africa"
Yes. Aim: to investigate possible transmission of
EBOV from an EVD survivor to another person
Yes. Aim: "to assess the presence and duration of
EBOV and viral RNA in semen and other body
fuids of EVD survivors"
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Study

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
N/A; modeling
study

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

N/A

N/A

Lee et al
(2017)

N/A; the study's
purpose was to
report on
recrudescence events
in West Africa

N/A

Luo et al
(2019)

N/A; modeling
study

Recrudescent Ebola was
defined as "reappearance of
at least one confirmed case
of EVD in a country where
the end of EVD had been
declared in advance"
N/A

Yes. Aim: "to compute the probability of the end
of an Ebola virus disease epidemic, accounting
for sexual transmission and underascertainment
of cases"
Yes. Aim: "to review all known recrudescence
events in West Africa occurring during the
period 2014–2016"

Martini et
al (1968)

Unclear, probably
yes

Viral culture

Unclear

Mate et al
(2015)

N/A; the study's
purpose was to use
genomic data to
demonstrate sexual
transmission from a
survivor

Positive result by RT-PCR

N/A

Lee et al
(2019)

N/A

Yes. Aim: " to understand how the [West African
epidemic was affected by various transmission
routes which include contact with infections,
contact with dead bodies, and having sex with
convalescent survivors"
Not specifically Ebola, but the study was a case
report on sexual transmission of the related
Marburg virus
Yes. Aim: to use genomic analysis to provide
evidence of sexual transmission of EBOV and
evidence of persistence of infective EBOV in
semen

53

Study

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
Moreau et N/A; the study's
al (2015)
purpose was to
report on two Ebola
virus (EBOV) RTPCR discordant
mother–child pairs
PREVAIL Unclear, probably
et al
yes
(2019)

Purpura et Unclear, probably
al (2017)
yes
Richards
et al
(2000)

Unclear, probably
yes

Rodriguez
et al
(1999)

Unclear, probably
yes

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

Positive result by RT-PCR

Unclear

Not exactly from survivors. Aim: to investigate
two Ebola virus RT-PCR discordant motherchild pairs to suggest the need for RT-PCR
testing of breastmilk

For antibody specimens:
"548 enzyme-linked
immunosorbent assay units
(EU) per milliliter was used
as the cutoff for positivity";
For semen specimens:
positive result by RT-PCR
Positive result by RT-PCR

Unclear

Yes. Aim: "describes the investigation by the
Government of Liberia and international
response partners of the source of Liberia’s latest
Ebola case and discusses the public health
implications of possible sexual transmission of
Ebola virus"

Unclear

EBOV isolation by viral
culture, as well as using
ELISA and IgM antibodies
for viral
antigen detection by ELISA
Positive laboratory result for
Ebola virus antigen by
reverse transcriptase
qualitative PCR (RT-PCR)

Unclear

Yes. Aim: " to report an EVD survivor with
preexisting HIV infection, whose semen was
positive for Ebola virus RNA 565 days after
recovery from EVD"
Yes. Aim: "To describe the clinical
manifestations of viral hemorrhagic fever, and to
increase clinicians' awareness and knowledge of
these illnesses"

Unclear

Yes. Aim: "to determine whether EBO virus is
still present in body fluids of convalescent
patients after clinical symptoms subside, and if
so, what the duration of virus persistence is"
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Study

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

Yes. Aim: "to describe the clinical course of
convalescence following EHF, determine
whether body fluids contain EBO virus, and
monitor household contacts for evidence of
secondary transmission from the convalescents"

Not exactly about survivors. Aim: to investigate
the case of a 9-month-old infant died from Ebola
virus (EBOV) disease with unknown
epidemiological link. The parents may have had
asymptomatic carriage

detection of virus RNA or
by viral culture

Rowe et al Unclear, probably
(1999)
yes

Positive result by RT-PCR

Sissoko et
al (2017)

Positive result by RT-PCR

No, but the
authors
attempted to
select 2 controls
of the same sex
as and close in
age to the
convalescent
Unclear

Positive result by RT-PCR

Unclear

Sissoko et
al (2017)

Yes, "We processed
samples of seminal
fluid from
participants
immediately after
collection at the
European mobile
laboratory (EMLab)
unit in Coyah"
Unclear, probably
yes

Yes. Aim: "to use biostatistical modelling to
describe the dynamics of Ebola virus RNA load
in seminal fluid, including clearance parameters"
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Study

Soka et al
(2016)

Sow et al
(2016)
Srinivas et
al (2016)

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
Yes, "All selfcollected semen
specimens submitted
by the MHSP were
stored and
transported at –20°C
or colder to the
Tappita Ebola virus
disease laboratory in
Nimba County.
Upon receipt in the
laboratory,
specimens were
maintained at –20°C
or colder until
testing"
Unclear, probably
yes

Unclear, probably
yes, as this person
was placed under
quarantine
Subtil et al Unclear, probably
(2017)
yes

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

Positive result by RT-PCR

Unclear

Yes. Aim: "describe Liberia’s national semen
testing programme for Ebola virus, present
preliminary semen testing results, and report
sexual risk behaviours"

Positive result by RT-PCR

Unclear

Positive result by RT-PCR
or viral isolation by culture

Unclear

Yes. Aim: "report new evidence of long-term
persistence of Ebola virus RNA in semen of
male survivors"
Yes. Aim: "report follow-up of a man who
recovered from EVD and was monitored for 165
days after he was declared Ebola-free"

Positive result by RT-PCR,
with a Ct cutoff for
positivity of ≤40.9

Unclear

Yes. Aim: "This study modeled the presence of
Ebola virus RNA in the semen of male Ebola
survivors participating in the Postebogui study in
Guinea"
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Study

Toure et
al (2017)

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
Unclear, probably
yes

Uyeki et al Yes. "Semen
(2016)
specimens were
collected and
transported as soon
as possible or
maintained at 4
degrees Celsius and
shipped overnight
on frozen cold packs
to CDC. The
majority of the
specimens were
processed within 0–
3 days; however a
few were processed
5–8 days after
collection. Only one
specimen that was
collected 290 days
post symptom onset
was frozen prior to
virus culture"

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

Detection of antibodies to
GP, NP and VP40 proteins
and of EBOV RNA in
semen by PCR

Unclear

Positive result by RT-PCR;
cycle threshold (Ct) values
<40 were considered
positive; viral isolation by
culture was also performed

Unclear

Yes. Aim: "to quantify individual risk of exposure
of contact persons to EVD cases; to measure the
presence of antibodies to EBOV; to look for
EBOV RNA in semen of adult seropositive
men"
Yes. Aim: "[to investigate] the duration of Ebola
virus (EBOV) RNA and infectious EBOV in
semen specimens of 5 Ebola virus disease (EVD)
survivors"
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Study

Zeng et al
(2016)

Acceptable time
delay between
sample collection
& testing (< 3
months for
assessment of
exposures)
N/A; the study's
purpose was to
assess the viability of
rhesus monkeys as
an animal model for
EBOV persistence

Case definition & method
of Ebola status
confirmation

Were the
samples
duplicatetested?

Was the aim relevant to human-to-human
sexual transmission or transmission from
survivors?

N/A

N/A

Yes. Aim: "to provide an animal model that
demonstrates EBOV persistence is associated
with ongoing replication in the presence of an
inflammatory host response"
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Supplementary Table 3. Data for Weighted Average Calculation for Length of Persistence of EBOV RNA in Semen
Reference

Abel et al (2017)
Fischer et al (2017)
Rodriguez et al (1999),
Rowe et al (1999)
Sissoko et al (2017)
Sow et al (2016)
Uyeki et al (2016)
Barnes et al (2017)
Bausch et al (2007)
Christie et al (2015),
Mate et al (2015)
Diallo et al (2016)
Green et al (2016)
Purpura et al (2017)
Srinivas et al (2016)
Weighted Average
Weighted SD
N

No. of Patients

No. of Patients
with Positive
Sample (%)

Mean Time Between Disease Onset and
Last Positive Sample

Weight

188
149
5

15
13
4

190.4 +/- 155.1*
771.9 +/- 100.9
85.8 +/- 17.2

0.41964286
0.33258929
0.01116071

26
68
5
1
1
1

19
8
5
1
1
1

149.6 +/- 91.2
118.9 +/- 79.9
184.6 +/- 75.3
110
40
199

0.05803571
0.15178571
0.01116071
0.00223214
0.00223214
0.00223214

1
1
1
1

1
1
1
1

531
128
579
179

0.00223214
0.00223214
0.00223214
0.00223214

370.3149554 Note: * denotes that the value was measured as days since discharge from ETC
345.077
448

59

Supplementary Table 4. Data for Analysis of Age & Duration of EBOV RNA Persistence in
Seminal Fluids of EVD Survivors
Reference
Abel et al (2017)
Abel et al (2017)
Abel et al (2017)
Abel et al (2017)
Barnes et al (2017)
Christie et al (2015),
Mate et al (2015)
Diallo et al (2016)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Fischer et al (2017)
Green et al (2016)
Purpura et al (2017)
Rodriguez et al (1999)
Rodriguez et al (1999)
Rodriguez et al (1999)
Rodriguez et al (1999)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)

Body
Fluid
Semen
Semen
Semen
Semen
Semen
Semen

Assay

Age

Latest Day After ADisease
Onset: Positive Sample

RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR

56
26
29
37
34
46

511
467
209
90
110
199

Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen

RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR

56
47
54
34
36
38
46
43
36
46
44
42
43
41
21
48
25
27
29
33
40
45
35
18
33
26
30
46

531
965
849
737
905
676
560
762
761
734
828
749
750
759
128
579
101
82
63
63
254
168
251
177
407
233
158
168
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Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sissoko et al (2017)
Sow et al (2016)
Sow et al (2016)
Sow et al (2016)
Sow et al (2016)
Sow et al (2016)
Sow et al (2016)
Sow et al (2016)
Sow et al (2016)
Srinivas et al (2016)

Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen
Semen

RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR

19
28
27
32
32
28
40
35
18
55
25
48
28
27
27
48
19
37
58
26

184
177
57
94
72
103
38
61
72
73
95
276
30
56
61
182
93
99
218
179

61

Supplementary Table 5. Studies Eligible for Analysis of Intermittent Detection Data
Reference
Abel et al (2017),
Subtil et al (2017)
Barnes et al (2017)
Christie et al
(2015), Mate et al
(2015)
Emond et al
(1977)
Fischer et al (2017)
PREVAIL III
Study Group
(2019)
Purpura et al
(2017)
Sissoko et al
(2017)
Total
Proportions

Number of people
with fluctuating
results

Number of people with 2 –
‘s before a + (if applicable)
8

Total Number
of People
Tested
0
15

0
0

0
0

1
1

0

0

1

8
78

1
36

13
252

1

1

1

0

0

19

95
0.313531353

38
0.125412541

303
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Supplementary Table 6a. Samples that demonstrated intermittent detection of EBOV RNA
Reference

Abel et al
(2017)

Fischer et
al (2017)

Total
Length of
Follow-Up
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset

-

+

-

66

397

453

463

+

-

+

-

-

195

265

414

424

435

-

+

-

-

-

42

76

128

245

327

-

+

-

779

849

980

-

+

-

-

-

725

737

779

926

975

+

+

-

+

-

648

660

732

905

954

-

+

-

-

-

-

657

676

725

788

957

1005

Length of FollowUp from Last
Positive to Last
Sample
10

240

21

285

251

201

131

250

238

306

49

348

329
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Purpura et
al (2017)

RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset

+

+

-

+

-

-

610

624

713

762

910

958

+

-

+

-

-

-

-

643

657

734

781

802

922

970

-

+

+

-

707

719

749

791

-

-

+

-

650

692

750

972

(previ
ous +
tests)
406

-

-

+

-

-

532

548

565

603

624

(more
tests)
758

348

196

327

236

84

42

322

222

352

193

64

Supplementary Table 6b. Samples that did not demonstrate intermittent detection of EBOV RNA
Reference
Barnes et
al (2017)
Christie et
al (2015),
Mate et al
(2015)
Emond et
al (1977)
Sissoko et
al (2017)

RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
Viral Culture
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset

+

+

+

-

-

32

66

110

180

244

+

-

-

199

231

234

+

+

-

-

-

39

61

76

92

110

+

-

-

254

N/A

338

+

-

-

168

N/A

270

+

-

-

251

N/A

336

+

-

-

177

N/A

255

Total
Length of
Follow-Up
212

Length of Follow-Up
from Last Positive to Last
Sample
134

35

35

71

49

84

84

102

102

85

85

78

78

65

RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result
Day After
Disease Onset
RT-PCR
Result

+

-

-

168

N/A

236

+

-

-

184

N/A

254

+

-

-

177

N/A

282

+

-

-

57

N/A

243

+

-

-

94

N/A

274

+

-

-

72

N/A

268

+

-

-

103

N/A

242

+

-

-

38

N/A

225

+

-

-

68

68

70

70

105

105

186

186

180

180

196

196

139

139

187

187

57

57

66

Day After
Disease Onset

61

N/A

118

67

